{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:08:19Z","timestamp":1788433699503,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41375-026-02861-1","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T08:56:24Z","timestamp":1770195384000},"page":"681-684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Accumulation of high-risk genetic features after chemoimmunotherapy: A longitudinal study in mantle cell lymphoma"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1451-0699","authenticated-orcid":false,"given":"Anna","family":"Nikkarinen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Alml\u00f6f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8749-7299","authenticated-orcid":false,"given":"Albin","family":"\u00d6sterroos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7501-6598","authenticated-orcid":false,"given":"Claes","family":"Ladenvall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0901-5252","authenticated-orcid":false,"given":"Rose-Marie","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0226-5681","authenticated-orcid":false,"given":"Peter","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Ayoola Gustafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5634-7156","authenticated-orcid":false,"given":"Panagiotis","family":"Baliakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6158-3041","authenticated-orcid":false,"given":"Ingrid","family":"Glimelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"2861_CR1","doi-asserted-by":"publisher","first-page":"e928","DOI":"10.1097\/HS9.0000000000000928","volume":"7","author":"M Jerkeman","year":"2023","unstructured":"Jerkeman M, Ekberg S, Glimelius I, Albertsson-Lindblad A, Entrop JP, Ellin F, et al. Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma: The Swedish MCLcomplete Project. Hemasphere. 2023;7:e928.","journal-title":"Hemasphere"},{"key":"2861_CR2","doi-asserted-by":"crossref","unstructured":"Khouja M, Jiang L, Pal K, Stewart PJ, Regmi B, Schwarz M, et al. Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials. Leukemia. 2024;38:2675\u20132684.","DOI":"10.1038\/s41375-024-02375-8"},{"key":"2861_CR3","unstructured":"Yi S, Yan Y, Jin M, Bhattacharya S, Wang Y, Wu Y, et al. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J Clin Invest. 2022;132:e153283."},{"key":"2861_CR4","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/gcc.22849","volume":"59","author":"L Streich","year":"2020","unstructured":"Streich L, Sukhanova M, Lu X, Chen YH, Venkataraman G, Mathews S, et al. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A\/B loss, and TP53 mutations: A multi-institutional study. Genes Chromosomes Cancer. 2020;59:484\u201394.","journal-title":"Genes Chromosomes Cancer"},{"key":"2861_CR5","doi-asserted-by":"crossref","unstructured":"Wan H, Ren W, Yang M, Nie M, Wasik AM, Du L, et al. Tumor evolution and immune microenvironment dynamics in primary and relapsed mantle cell lymphoma. Cell Rep Med. 2025;6:102318.","DOI":"10.1016\/j.xcrm.2025.102318"},{"key":"2861_CR6","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/ajh.27044","volume":"98","author":"J Karolov\u00e1","year":"2023","unstructured":"Karolov\u00e1 J, Kazantsev D, Svato\u0148 M, Tu\u0161kov\u00e1 L, Forsterov\u00e1 K, Mal\u00e1rikov\u00e1 D, et al. Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy. Am J Hematol. 2023;98:1627\u201336.","journal-title":"Am J Hematol"},{"key":"2861_CR7","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1182\/bloodadvances.2023011763","volume":"8","author":"C L\u00f3pez","year":"2024","unstructured":"L\u00f3pez C, Silkenstedt E, Dreyling M, Be\u00e0 S. Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma. Blood Adv. 2024;8:3652\u201364.","journal-title":"Blood Adv"},{"key":"2861_CR8","doi-asserted-by":"crossref","unstructured":"Meriranta L, Rask Kragh J\u00f8rgensen R, Pasanen A, Kolstad A, et al. Circulating Tumor DNA Determinants of Response and Outcome in Relapsed\/Refractory Mantle Cell Lymphoma. Blood Adv. 2025;9:4528-4541.","DOI":"10.1182\/bloodadvances.2025015791"},{"key":"2861_CR9","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1182\/blood.2019003539","volume":"135","author":"CW Eskelund","year":"2020","unstructured":"Eskelund CW, Husby S, Favero F, Klausen TW, Rodriguez-Gonzalez FG, Kolstad A, et al. Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL. Blood. 2020;135:2000\u20134.","journal-title":"Blood"},{"key":"2861_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1182\/blood.2023022354","volume":"145","author":"P Jain","year":"2025","unstructured":"Jain P, Wang M. High-risk MCL: recognition and treatment. Blood. 2025;145:683\u201395.","journal-title":"Blood"},{"key":"2861_CR11","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1182\/blood.2020005289","volume":"136","author":"F Nadeu","year":"2020","unstructured":"Nadeu F, Martin-Garcia D, Clot G, D\u00edaz-Navarro A, Duran-Ferrer M, Navarro A, et al. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood. 2020;136:1419\u201332.","journal-title":"Blood"},{"key":"2861_CR12","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1038\/s41588-019-0525-5","volume":"51","author":"O Pich","year":"2019","unstructured":"Pich O, Mui\u00f1os F, Lolkema MP, Steeghs N, Gonzalez-Perez A, Lopez-Bigas N. The mutational footprints of cancer therapies. Nat Genet. 2019;51:1732\u201340.","journal-title":"Nat Genet"},{"key":"2861_CR13","doi-asserted-by":"crossref","unstructured":"Parry EM, Okosun J. An updated understanding of follicular lymphoma transformation. Blood. 2025;146:1812\u20131823.","DOI":"10.1182\/blood.2024026016"},{"key":"2861_CR14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ajh.25796","volume":"95","author":"S Zhao","year":"2020","unstructured":"Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020;95:623\u20139.","journal-title":"Am J Hematol"},{"key":"2861_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S1470-2045(24)00732-0","volume":"26","author":"I Glimelius","year":"2025","unstructured":"Glimelius I. Mantle cell lymphoma: is it time for risk-adapted treatment? Lancet Oncol. 2025;26:150\u20132.","journal-title":"Lancet Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02861-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02861-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02861-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:38:10Z","timestamp":1772609890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02861-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2861"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02861-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.N. No conflicts of interest J.A. No conflicts of interest A.\u00d6. No conflicts of interest C.L. No conflicts of interest R-M.A. No conflicts of interest P.H. No conflicts of interest K.A.G. No conflicts of interest P.B. No conflicts of interest I.G. received research support for the department from Takeda and participated in educational sessions arranged by Janssen Cilag, AbbVie and Kite Gilead with all support to the department.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}